GSK noted recent deals as source of fresh revenues amid patent expiries and an AI-driven boost to drug discovery.

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc ("GSK ...

The FDA has told the makers of six flu vaccines that they need to add a notification to the label of their shots, warning of ...

GSK is shifting to specialty growth (HIV, oncology, asthma) with key launches and a deep late-stage pipeline—still ...

Noetik CEO and co-founder Ron Alfa, M.D., Ph.D., said the licensing of human foundation models is “a new paradigm in biotech.” With the GSK deal validating the paradigm, in Alfa’s view, Noetik ...

GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.

If you are wondering whether GSK shares still offer value at around £18.86, you are not alone. The stock has been attracting ...

In addition to Morgan Stanley, GlaxoSmithKline also received a Sell from J.P. Morgan’s Zain Ebrahim in a report issued today. However, on January 8, Deutsche Bank maintained a Hold rating on ...

Samsung Biologics, a biotechnology company based in South Korea, announced plans to open its first U.S. manufacturing ...

AnaptysBio said on Thursday it filed a partial motion to dismiss a claim by GSK's oncology unit, which alleges the biotech ...

GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, setting up the pharma for a push to the FDA.

GSK will use promising results from two studies of its experimental chronic hepatitis B therapy to support planned regulatory ...